Loading...
NRIX logo

Nurix Therapeutics, Inc.NasdaqGM:NRIX Stok Raporu

Piyasa Değeri US$1.6b
Hisse Fiyatı
US$16.42
US$30.18
45.6% değerinin altında içsel indirim
1Y67.9%
7D1.5%
Portföy Değeri
​
Görünüm

Nurix Therapeutics, Inc.

NasdaqGM:NRIX Stok Raporu

Piyasa değeri: US$1.6b

Nurix Therapeutics (NRIX) Hisse Özeti

Klinik aşamada bir biyofarmasötik şirketi olan Nurix Therapeutics, Inc. kanser, enflamatuar durumlar ve diğer hastalıkların tedavisi için küçük molekül ve antikor tedavilerinin keşfi, geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Daha fazla detay

Ödüller

Gelirin yılda 42.24% oranında artması öngörülüyor

Analistler hisse senedi fiyatının 83.8% oranında artacağı konusunda hemfikir

Risk Analizi

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor


NRIX Community Fair Values

Create Narrative

See what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Nurix Therapeutics, Inc. Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Nurix Therapeutics
Tarihsel hisse senedi fiyatları
Güncel Hisse FiyatıUS$16.42
52 Haftanın En Yüksek SeviyesiUS$22.50
52 Haftanın En Düşük SeviyesiUS$8.20
Beta1.88
1 Aylık Değişim-3.64%
3 Aylık Değişim3.99%
1 Yıllık Değişim67.89%
3 Yıllık Değişim66.36%
5 Yıllık Değişim-37.83%
Halka arzdan bu yana değişim-13.62%

Son Haberler & Güncellemeler

Seeking Alpha • Apr 09

Nurix: 'Strong Buy' Bexobruditeg Development And Dual Degrader Zelebrudomide

Summary Nurix Therapeutics, Inc. maintains a Strong Buy rating, driven by the advancement of bexobrutideg for relapsed/refractory CLL in pivotal phase 2 trials. Company is set to initiate a global phase 3 confirmatory trial for bexobrutideg in mid-2026, targeting patients post-BTK therapy and benchmarking against pirtobrutinib. Expansion efforts include higher-dose bexobrutideg for earlier CLL lines, an oral formulation for immunology, and the dual BTK/IKZF degrader zelebrudomide for B-cell malignancies. While cash reserves stand at $540.7M, NRIX faces a 12-month runway and will require additional funding to sustain its R&D-intensive pipeline. Read the full article on Seeking Alpha
Analiz Makalesi • Nov 16

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock Rockets 30% As Investors Are Less Pessimistic Than Expected

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shareholders have had their patience rewarded with a 30% share price jump in...

Recent updates

Seeking Alpha • Apr 09

Nurix: 'Strong Buy' Bexobruditeg Development And Dual Degrader Zelebrudomide

Summary Nurix Therapeutics, Inc. maintains a Strong Buy rating, driven by the advancement of bexobrutideg for relapsed/refractory CLL in pivotal phase 2 trials. Company is set to initiate a global phase 3 confirmatory trial for bexobrutideg in mid-2026, targeting patients post-BTK therapy and benchmarking against pirtobrutinib. Expansion efforts include higher-dose bexobrutideg for earlier CLL lines, an oral formulation for immunology, and the dual BTK/IKZF degrader zelebrudomide for B-cell malignancies. While cash reserves stand at $540.7M, NRIX faces a 12-month runway and will require additional funding to sustain its R&D-intensive pipeline. Read the full article on Seeking Alpha
Analiz Makalesi • Nov 16

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Stock Rockets 30% As Investors Are Less Pessimistic Than Expected

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shareholders have had their patience rewarded with a 30% share price jump in...
Analiz Makalesi • Oct 12

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Third-Quarter Results: Here's What Analysts Are Forecasting For Next Year

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) missed earnings with its latest quarterly results, disappointing...
Analiz Makalesi • Sep 30

Subdued Growth No Barrier To Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Price

With a median price-to-sales (or "P/S") ratio of close to 10x in the Biotechs industry in the United States, you could...
Analiz Makalesi • Aug 18

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

NasdaqGM:NRIX 1 Year Share Price vs Fair Value Explore Nurix Therapeutics's Fair Values from the Community and select...
Analiz Makalesi • Jul 14

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shareholders will have a reason to smile today, with the analysts making...
Analiz Makalesi • May 12

Shareholders Will Probably Hold Off On Increasing Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) CEO Compensation For The Time Being

Key Insights Nurix Therapeutics' Annual General Meeting to take place on 19th of May CEO Arthur Sands' total...
Seeking Alpha • Apr 17

Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential

Summary FDA IND clearance given for BTK degrader GS-6791, targeting inflammatory disorders, allowing Nurix Therapeutics, Inc. to receive a $5 million milestone payment from Gilead Sciences. Nurix has earned $135 million from its Gilead collaboration and could earn up to a total of $420 million in milestone payments for developing up to five protein degraders. Nurix's wholly owned BTK degrader Bexobrutideg is in phase 1b trials for relapsed/refractory B-cell malignancies, with plans to target inflammatory and autoimmune disorders as well. Besides the partnership with Gilead Sciences, the company is advancing its STAT6 protein degrader with Sanofi and antibody drug conjugate degraders as a new class of drugs to target disorders with Pfizer. Read the full article on Seeking Alpha
Analiz Makalesi • Apr 17

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shareholders will have a reason to smile today, with the analysts making...
Analiz Makalesi • Mar 22

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares May Have Slumped 25% But Getting In Cheap Is Still Unlikely

Unfortunately for some shareholders, the Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) share price has dived 25% in the last...
Seeking Alpha • Feb 18

Nurix Therapeutics: A Story To Monitor

Summary Nurix Therapeutics, Inc.'s shares have dropped some 40% due to limited 2025 data catalysts, despite promising Phase 1 results for NX-5948 in CLL, targeting pivotal trials in 2025. Nurix's DELigase platform leverages E3 ligases for protein modulation, aiming to degrade or elevate proteins, offering advantages over CRISPR and RNA interference methods. NX-5948 shows strong efficacy in heavily pre-treated CLL patients, with Fast Track and PRIME designations, but faces competition from BeiGene's similar BTK degrader. An initial analysis around NRIX stock follows in the paragraphs below. Read the full article on Seeking Alpha
Analiz Makalesi • Jan 30

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

We can readily understand why investors are attracted to unprofitable companies. By way of example, Nurix Therapeutics...
Seeking Alpha • Jan 05

Nurix Therapeutics: Still A Cool Story, But This Price Point Remains Too Hot For Me

Summary Nurix Therapeutics (NRIX) focuses on protein degradation in cancer treatment, with a current valuation of $1.4 billion and promising early-stage clinical data. NX-5948, a BTK degrader, shows high response rates in B-cell malignancies, with manageable safety profiles and FDA Fast Track designations. Financially, NRIX holds $99 million in cash and $349 million in marketable securities, but faces risks of future dilution and high execution expectations. Despite compelling early data, NRIX's high valuation and market hype suggest waiting for better entry points, making it a "Hold" for now, in my opinion. Read the full article on Seeking Alpha
Analiz Makalesi • Nov 07

Subdued Growth No Barrier To Nurix Therapeutics, Inc. (NASDAQ:NRIX) With Shares Advancing 25%

Despite an already strong run, Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shares have been powering on, with a gain of...
Analiz Makalesi • Oct 31

Companies Like Nurix Therapeutics (NASDAQ:NRIX) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Nurix...
Seeking Alpha • Oct 08

Nurix: An Attractive Early-Stage Biotech Play

Summary Nurix Therapeutics, specializing in targeted protein degradation, shows promise with its clinical-stage candidates NX-1607, NX-5948, and NX-2127 for cancer and autoimmune diseases. Strong partnerships with Sanofi, Gilead, and Pfizer bolster Nurix's funding and technological capabilities, enhancing its potential for successful drug development and commercialization. Despite operating at a loss, Nurix's solid cash position and positive clinical trial results make it a compelling buy opportunity, though risks remain. Nurix's innovative approach and potential regulatory approvals make it a strong investment candidate for those seeking high-risk, high-reward opportunities. Read the full article on Seeking Alpha
Analiz Makalesi • Sep 07

Unpleasant Surprises Could Be In Store For Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) Shares

Nurix Therapeutics, Inc.'s ( NASDAQ:NRIX ) price-to-sales (or "P/S") ratio of 24.1x might make it look like a strong...
Seeking Alpha • Sep 04

Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data

Summary Nurix Therapeutics leverages the ubiquitin-proteasome system for targeted protein degradation (TPD) and elevation (TPE) in cancer and autoimmune diseases, with promising early-stage clinical data. Key programs include BTK, IKZF, and CBL-B targets, with notable molecules NX-5948, NX-2127, and NX-1607 showing potential in heavily pretreated B-cell malignancies. Strategic partnerships with Gilead, Sanofi, and Pfizer provide substantial financial backing, with up to $8.1 billion in potential milestone payments. Despite high valuation and limited near-term data catalysts, Nurix's innovative approach and big pharma interest warrant continued observation for future investment opportunities. Read the full article on Seeking Alpha
Analiz Makalesi • Jul 15

Nurix Therapeutics (NASDAQ:NRIX) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, Nurix Therapeutics...
Seeking Alpha • Jun 19

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

Summary Nurix Therapeutics raised $209m in its IPO in July 2020, focusing on protein degradation in drug development, primarily in the blood cancer space. Protein degradation involves marking proteins for destruction by the proteasome using bifunctional small molecules. Nurix's lead proprietary candidate NX-5948 showed promising results in a Phase 1a clinical study for CLL patients in data released this week, triggering a surge in the company's share price. Management hopes to guide its lead candidate into a pivotal study next year, opening up a potentially compelling market opportunity. More data - in NHL and immuno-oncology - will arrive this year, and Nurix continues to collaborate with three major Pharma companies - Gilead, Sanofi, and Pfizer. The bull run can therefore be sustained. Read the full article on Seeking Alpha
Analiz Makalesi • May 29

What Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 26% Share Price Gain Is Not Telling You

The Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) share price has done very well over the last month, posting an excellent...
Seeking Alpha • Apr 15

Nurix Therapeutics Advances Promising Protein Degraders For B-Cell Malignancies

Summary Nurix Therapeutics raises $175 million in an upsized offering after a 168% stock return in the past six months. The biotech company is developing protein degraders, with NX-2127 and NX-5948, targeting B-cell malignancies. Nurix's protein degraders are focused on BTK, a target also addressed by Johnson & Johnson's popular drug Imbruvica. Hold rating advised: High-risk, high-reward due to innovative approach and competitive market; efficacy and safety data needed. Read the full article on Seeking Alpha
Analiz Makalesi • Apr 14

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 28% Price Boost Is Out Of Tune With Revenues

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shares have continued their recent momentum with a 28% gain in the last month...
Analiz Makalesi • Feb 20

Improved Revenues Required Before Nurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Find Their Feet

With a price-to-sales (or "P/S") ratio of 6.3x Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) may be sending very bullish...
Seeking Alpha • Jan 16

Nurix Therapeutics: Recovering Thanks To ASH, But I Think It's Priced Just Right For Now

Summary Nurix Therapeutics remains a highly interesting science project, but the rubber has yet to hit the road on their clinical projects. The company's BTK degraders are showing early signs of life, but the competition in the market and expenses are concerns. Nurix has enough assets to fund operations for another 6 to 7 quarters, but a cash infusion may be needed later this year. Read the full article on Seeking Alpha
Analiz Makalesi • Dec 29

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analiz Makalesi • Oct 14

Nurix Therapeutics, Inc.'s (NASDAQ:NRIX) 29% Dip In Price Shows Sentiment Is Matching Revenues

To the annoyance of some shareholders, Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shares are down a considerable 29% in...
Analiz Makalesi • Oct 13

Broker Revenue Forecasts For Nurix Therapeutics, Inc. (NASDAQ:NRIX) Are Surging Higher

Shareholders in Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) may be thrilled to learn that the analysts have just delivered...
Analiz Makalesi • Sep 30

Here's Why We're Watching Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analiz Makalesi • Apr 18

Party Time: Brokers Just Made Major Increases To Their Nurix Therapeutics, Inc. (NASDAQ:NRIX) Earnings Forecasts

Nurix Therapeutics, Inc. ( NASDAQ:NRIX ) shareholders will have a reason to smile today, with the analysts making...
Analiz Makalesi • Apr 15

We Think Nurix Therapeutics (NASDAQ:NRIX) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analiz Makalesi • Nov 28

We're Keeping An Eye On Nurix Therapeutics' (NASDAQ:NRIX) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Hissedar Getirileri

NRIXUS BiotechsUS Pazar
7D1.5%-3.0%-0.3%
1Y67.9%32.9%26.7%

Getiri vs. Endüstri: NRIX geçen yıl % 32.9 oranında getiri sağlayan US Biotechs sektörünü aştı.

Getiri vs Piyasa: NRIX geçen yıl % 26.7 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is NRIX's price volatile compared to industry and market?
NRIX volatility
NRIX Average Weekly Movement6.4%
Biotechs Industry Average Movement10.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.2%
10% least volatile stocks in US Market3.2%

İstikrarlı Hisse Senedi Fiyatı: NRIX son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: NRIX 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

KurulduÇalışanlarCEOWeb sitesi
2009317Arthur Sandswww.nurixtx.com

Klinik aşamada bir biyofarmasötik şirketi olan Nurix Therapeutics, Inc. kanser, enflamatuar durumlar ve diğer hastalıkların tedavisi için küçük molekül ve antikor tedavilerinin keşfi, geliştirilmesi ve ticarileştirilmesine odaklanmaktadır. Şirket, nükseden veya refrakter B-hücreli malignitelerin ve otoimmün hastalıkların tedavisi için Faz 2 klinik çalışmalarında olan, oral olarak biyolojik olarak kullanılabilir bir BTK parçalayıcı olan NX-5948'i geliştirmektedir; Nükseden veya refrakter B hücreli malignitelerin tedavisi için Faz 1a/1b klinik çalışmalarında olan, ağızdan biyolojik olarak alınabilen Bruton tirozin kinaz (BTK) parçalayıcı NX-2127; ve immüno-onkoloji endikasyonlarını tedavi etmek için Faz 1a/1b klinik çalışmalarında olan, ağızdan biyolojik olarak alınabilen Casitas B-lineage lenfoma proto-onkogen-B (CBL-B) inhibitörü NX-1607. Ayrıca, romatoid artrit ve diğer enflamatuar hastalıkların tedavisi için bir IRAK4 parçalayıcı olan NX-0479/GS-6791'i geliştirmektedir.

Nurix Therapeutics, Inc. Temel Bilgiler Özeti

Nurix Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
NRIX temel i̇stati̇sti̇kler
Piyasa değeriUS$1.58b
Kazançlar(TTM)-US$295.28m
Gelir(TTM)US$71.78m
23.7x
P/S Oranı
-5.8x
F/K Oranı

NRIX aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
NRIX gelir tablosu (TTM)
GelirUS$71.78m
Gelir MaliyetiUS$331.38m
Brüt Kâr-US$259.60m
Diğer GiderlerUS$35.68m
Kazançlar-US$295.28m

Son Raporlanan Kazançlar

Feb 28, 2026

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)-2.86
Brüt Marj-361.66%
Net Kâr Marjı-411.37%
Borç/Özkaynak Oranı0%

NRIX uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2026/05/20 06:12
Gün Sonu Hisse Fiyatı2026/05/20 00:00
Kazançlar2026/02/28
Yıllık Kazançlar2025/11/30

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Nurix Therapeutics, Inc. 25 Bu analistlerden 17, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Brian SkorneyBaird
Joel BeattyBaird
Zhiqiang ShuBerenberg